HIPAA Alert: Potential Data Breach Learn More

Questions on Oncology, Hematology and/or Infusion Clinical Services due to COVID-19 Crisis – CALL 833-698-1623
Important Information for Our Patients Regarding the Coronavirus.
RCCA Providing Area Cancer Patients with Access to Care During Coronavirus Outbreak
RCCA Offering Patients Virtual Visits During Coronavirus Pandemic

844-346-7222
Search
Close this search box.
844-346-7222
REQUEST AN APPOINTMENT
Facebook-f Twitter Linkedin-in
Print Friendly, PDF & Email

NCT/Study#

NCT04116437 /

BGB-3111-215

A Phase 2, Multicenter, Single-Arm Study Of Zanubrutinib (BGB-3111) In Patients With Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Intolerant Of Prior Treatment With Ibrutinib

Learn more
DISEASE GROUP:
Lymphoma
current phase:
Phase II
STUDY STATUS:
Accepting Patients
Location:
Hackensack, NJ
For More information:

Call 201-518-3587

Community Oncology Alliance Logo
COA Patient Advocacy Network Logo
The DAISY Award Partner Badge
OncLive® Strategic Alliance Partner Badge
Pharmacy Times® Strategic Alliance Partner Badge
Targeted Oncology Strategic Alliance Partner Badge